Seizures in PPT1 Knock-In Mice Are Associated with Inflammatory Activation of Microglia.
A 438079
PPT1 KI mice
hippocampus
microglia
seizures
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 May 2022
17 May 2022
Historique:
received:
26
03
2022
revised:
08
05
2022
accepted:
11
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Infantile neuronal ceroid lipofuscinosis (INCL), the most severe form of neuronal ceroid lipofuscinoses, is caused by mutations in the lysosomal enzyme palmitoyl protein thioesterase 1 (PPT1). Typical symptoms of this disease include progressive psychomotor developmental retardation, visual failure, seizures, and premature death. Here, we investigated seizure activity and relevant pathological changes in PPT1 knock-in mice (PPT1 KI). The behavior studies in this study demonstrated that PPT1 KI mice had no significant seizure activity until 7 months of age, and local field potentials also displayed epileptiform activity at the same age. The expression levels of Iba-1 and CD68 demonstrated, by Western blot analysis, the inflammatory cytokine TNF-α content measured with enzyme-linked immunosorbent assay, and the number of microglia demonstrated by immunohistochemistry (IHC) were significantly increased at age of 7 months, all of which indicate microglia activation at an age of seizure onset. The increased expression of GFAP were seen at an earlier age of 4 months, and such an increase reached its peak at age of 6 months, indicating that astrocyte activation precedes microglia. The purinergic P2X7 receptor (P2X7R) is an ATP-sensitive ionic channel that is highly expressed in microglia and is fundamental to microglial activation, proliferation, cytokines release and epilepsy. We show that the ATP concentration in hippocampal tissue in PPT1 KI mice was increased using an enhanced ATP assay kit and demonstrated that the antagonist of P2X7R, A-438079, significantly reduced seizures in PPT1 KI mice. In contrast to glial cell activation and proliferation, a significant reduction in synaptic proteins GABA
Identifiants
pubmed: 35628400
pii: ijms23105586
doi: 10.3390/ijms23105586
pmc: PMC9144763
pii:
doi:
Substances chimiques
Cytokines
0
Adenosine Triphosphate
8L70Q75FXE
Thiolester Hydrolases
EC 3.1.2.-
palmitoyl-protein thioesterase
EC 3.1.2.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Biochim Biophys Acta. 2013 Nov;1832(11):1842-65
pubmed: 23338040
Neurobiol Learn Mem. 2011 Mar;95(3):221-30
pubmed: 21093596
Pharmacol Ther. 2021 Aug;224:107821
pubmed: 33607148
Front Neurosci. 2017 Feb 02;11:21
pubmed: 28210205
Trends Neurosci. 2009 Jan;32(1):19-29
pubmed: 19008000
Toxicol Lett. 1992 Dec;64-65 Spec No:417-28
pubmed: 1335180
Front Cell Neurosci. 2013 Mar 28;7:32
pubmed: 23543873
Neuropharmacology. 2015 Sep;96(Pt A):11-8
pubmed: 25549562
J Neurol Sci. 1973 Mar;18(3):269-85
pubmed: 4121459
Br J Pharmacol. 2013 Oct;170(3):624-40
pubmed: 23889535
J Neuroinflammation. 2015 Nov 04;12:202
pubmed: 26538404
Signal Transduct Target Ther. 2021 Apr 17;6(1):160
pubmed: 33866328
Toxicol Pathol. 2007 Dec;35(7):984-99
pubmed: 18098044
Biochim Biophys Acta. 2015 Oct;1852(10 Pt B):2267-78
pubmed: 25937302
Glia. 2018 May;66(5):1016-1033
pubmed: 29380416
Curr Opin Neurol. 2003 Apr;16(2):121-8
pubmed: 12644737
Curr Opin Neurol. 2001 Dec;14(6):795-803
pubmed: 11723391
Glia. 2019 Oct;67(10):1821-1841
pubmed: 31033014
J Anat. 2017 Sep;231(3):366-379
pubmed: 28597918
Ann Clin Transl Neurol. 2014 Dec;1(12):1006-23
pubmed: 25574475
Nat Neurosci. 2013 Nov;16(11):1608-17
pubmed: 24056696
Mol Med Rep. 2019 Jun;19(6):5433-5439
pubmed: 31059094
J Neuroinflammation. 2020 Oct 28;17(1):323
pubmed: 33115477
J Neurosci Res. 2012 Feb;90(2):367-75
pubmed: 21971706
Psychopharmacology (Berl). 2020 Oct;237(10):2959-2966
pubmed: 32700022
J Neurosci. 2016 Jun 1;36(22):5920-32
pubmed: 27251615
Nat Neurosci. 2019 Mar;22(3):374-385
pubmed: 30718903
Neuroscience. 2016 Apr 5;319:35-45
pubmed: 26812038
Epilepsia. 2016 May;57(5):796-804
pubmed: 26996827
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13566-71
pubmed: 11717424
Curr Opin Neurol. 2001 Apr;14(2):187-92
pubmed: 11262734
Elife. 2019 Apr 04;8:
pubmed: 30946007
Curr Mol Med. 2002 Aug;2(5):423-37
pubmed: 12125808
J Cell Biol. 2018 Feb 5;217(2):459-472
pubmed: 29196460
Acta Neuropathol Commun. 2018 Aug 8;6(1):74
pubmed: 30089511
Brain Res. 2019 Nov 1;1722:146351
pubmed: 31351038
Nat Rev Neurosci. 2010 Mar;11(3):161-75
pubmed: 20168314
Neurobiol Dis. 2014 Feb;62:273-85
pubmed: 24141019
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):E197-205
pubmed: 22167804
Adv Neurol. 2002;89:211-5
pubmed: 11968447
Neurology. 2001 Aug 28;57(4):576-81
pubmed: 11548735
Brain. 2013 Apr;136(Pt 4):1083-101
pubmed: 23485853
Nat Med. 2004 Aug;10(8):821-7
pubmed: 15258577
Immunity. 2017 Jul 18;47(1):15-31
pubmed: 28723547
Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):
pubmed: 33753498
J Genet Eng Biotechnol. 2021 Aug 21;19(1):123
pubmed: 34417930
J Neurosci. 2014 Sep 24;34(39):13077-82
pubmed: 25253854
Neurobiol Dis. 2007 Jan;25(1):150-62
pubmed: 17046272
Epilepsia. 2009 Feb;50 Suppl 2:10-3
pubmed: 19187289
Epilepsia. 2005 Apr;46(4):470-2
pubmed: 15816939
Neural Netw. 2009 Oct;22(8):1113-9
pubmed: 19683412
Epilepsia. 1998 Jun;39(6):615-27
pubmed: 9637604
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
pubmed: 4110397
Trends Neurosci. 2007 Jul;30(7):309-16
pubmed: 17555828
Brain. 2004 Nov;127(Pt 11):2427-32
pubmed: 15371287
FASEB J. 2012 Apr;26(4):1616-28
pubmed: 22198387
Int J Mol Sci. 2020 Aug 20;21(17):
pubmed: 32825423
J Neuroimmunol. 2006 Apr;173(1-2):188-95
pubmed: 16483671
J Neurosci. 2009 Mar 25;29(12):3781-91
pubmed: 19321774
Hum Mol Genet. 2015 Jan 1;24(1):185-96
pubmed: 25205113
Methods Mol Biol. 2018;1727:127-137
pubmed: 29222778
CNS Neurosci Ther. 2014 Jun;20(6):556-64
pubmed: 24750893